Insider Selling: Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Sells 10,230 Shares of Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 10,230 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total value of $112,427.70. Following the completion of the transaction, the general counsel now owns 70,544 shares of the company’s stock, valued at $775,278.56. The trade was a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Mike Ouimette also recently made the following trade(s):

• On Friday, January 17th, Mike Ouimette sold 13,270 shares of Pliant Therapeutics stock. The shares were sold at an average price of $11.20, for a total transaction of $148,624.00.

Pliant Therapeutics Price Performance

Shares of PLRX traded down $0.15 during trading hours on Wednesday, hitting $10.92. The stock had a trading volume of 700,759 shares, compared to its average volume of 454,935. The stock has a market capitalization of $664.48 million, a price-to-earnings ratio of -3.27 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26. The company’s fifty day moving average is $13.24 and its two-hundred day moving average is $13.08. Pliant Therapeutics, Inc. has a 52 week low of $10.22 and a 52 week high of $18.92.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.04. On average, analysts anticipate that Pliant Therapeutics, Inc. will post -3.65 EPS for the current year.

Institutional Investors Weigh In On Pliant Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Great Point Partners LLC boosted its stake in Pliant Therapeutics by 42.4% in the second quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock worth $28,346,000 after purchasing an additional 785,000 shares in the last quarter. State Street Corp raised its holdings in shares of Pliant Therapeutics by 1.9% in the third quarter. State Street Corp now owns 1,402,730 shares of the company’s stock valued at $15,725,000 after buying an additional 26,610 shares during the last quarter. Geode Capital Management LLC lifted its position in Pliant Therapeutics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,318,308 shares of the company’s stock worth $14,781,000 after buying an additional 31,221 shares in the last quarter. Franklin Resources Inc. grew its holdings in Pliant Therapeutics by 1.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,039,904 shares of the company’s stock worth $11,657,000 after acquiring an additional 14,913 shares during the last quarter. Finally, Fernwood Investment Management LLC increased its position in Pliant Therapeutics by 3.4% in the 3rd quarter. Fernwood Investment Management LLC now owns 513,136 shares of the company’s stock valued at $5,752,000 after acquiring an additional 16,850 shares in the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a research report on Friday, November 8th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.